PTI Proteostasis Therapeutics Inc.

1.02
-0.02  -2%
Previous Close 1.04
Open 1.05
Price To Book 0.52
Market Cap 52,121,293
Shares 51,099,307
Volume 463,024
Short Ratio
Av. Daily Volume 1,393,851

Drug Information

Drug catalyst information is displayed when you hover over the stage bar graph.

Phase 2 28-day data released December 11, 2017 - showed improvements in FEV1 of 5.2%. Phase 2 28-day data released December 11, 2017 - showed improvements in FEV1 of 5.2%.
PTI-428
Cystic fibrosis
Development to be discontinued due to lack of efficacy - March 25, 2019.
PTI-801 + Symdeko
Cystic fibrosis
Proceed to 28 day studies to confirm efficacy.
PTI-801 and PTI-808
Cystic fibrosis
Phase 2 trial planned with enrolment to be completed by YE 2019.
PTI-428 + PTI-801 + PTI-808
Cystic fibrosis
Development to be discontinued due to lack of efficacy.
PTI-428 + Symdeko
Cystic fibrosis

Latest News

  1. How Proteostasis Therapeutics, Inc. (NASDAQ:PTI) Could Add Value To Your Portfolio
  2. Proteostasis Therapeutics Receives Orphan Drug Designation in the EU for PTI-428 for the Treatment of Cystic Fibrosis
  3. Proteostasis Therapeutics Announces Presentations and Hosts Educational Symposium at the 42nd European Cystic Fibrosis Conference
  4. Vertex Selects Triple Combo Regimen for Regulatory Submission
  5. Proteostasis Therapeutics to Present at the 2019 RBC Capital Markets Global Healthcare Conference
  6. Proteostasis Therapeutics Appoints Dr. Badrul Chowdhury, Former FDA Director of Pulmonology, Allergy, and Rheumatology, to Board of Directors
  7. Proteostasis Therapeutics (PTI) Reports Q1 Loss, Tops Revenue Estimates
  8. Proteostasis: 1Q Earnings Snapshot
  9. Proteostasis Therapeutics Reports First Quarter 2019 Financial Results and Provides Corporate Update
  10. Proteostasis (PTI) to Post Q1 Earnings: What's in Store?
  11. Market Sentiment Around Loss-Making Proteostasis Therapeutics, Inc. (NASDAQ:PTI)
  12. Analysts Estimate Proteostasis Therapeutics (PTI) to Report a Decline in Earnings: What to Look Out for
  13. Implied Volatility Surging for Proteostasis Therapeutics (PTI) Stock Options
  14. Proteostasis Plunges on Weak Data From Cystic Fibrosis Study
  15. Some Proteostasis Therapeutics (NASDAQ:PTI) Shareholders Have Taken A Painful 86% Share Price Drop
  16. The Daily Biotech Pulse: Japanese Cheer For AbbVie, Myokardia Offering, CytomX CFO Departs
  17. Why Vertex's Grip On This Huge Sales Opportunity Now Looks Unbreakable
  18. Proteostatis stock plunges on cystic fibrosis triple combo data
  19. Proteostasis Therapeutics Announces Broad New Dataset from Proprietary Combination and Add-On CFTR Modulator Studies in Cystic Fibrosis Patients